Pharmalink is a Swedish specialty pharma company developing high value products for niche indications. Pharmalink draws on its extensive experience of pharmaceutical product development and the excellence of medical science in Sweden to identify and progress products that address significant unmet medical needs. Pharmalink has introduced more than 15 pharmaceutical products to the market.

Using a repurposing and reformulation strategy, Pharmalink minimises the risk of product development. The Company’s strategy is to develop drugs to clinical proof-of-concept and then to out-license to a commercial partner.

Pharmalink’s model is exemplified by the successful development and divestment of its lead project, Xepol^®, in June 2010 with all intellectual property and assets related to the product acquired by Grifols. Pharmalink currently has two additional clinical phase development projects, Nefecon^®, and Busulipo^TM, mature for out-licensing to a commercial partner. The Company is actively in-licensing promising new projects to add to its pipeline.